CRISPR Therapeutics AG (NASDAQ:CRSP) Director John Greene Buys 7,000 Shares of Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) Director John Greene purchased 7,000 shares of the business’s stock in a transaction dated Wednesday, February 26th. The shares were purchased at an average price of $44.85 per share, for a total transaction of $313,950.00. Following the acquisition, the director now owns 7,000 shares of the company’s stock, valued at approximately $313,950. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

CRISPR Therapeutics Stock Up 0.7 %

Shares of NASDAQ:CRSP opened at $43.92 on Friday. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $89.88. The stock has a market capitalization of $3.77 billion, a P/E ratio of -10.05 and a beta of 1.67. The firm has a fifty day simple moving average of $42.42 and a two-hundred day simple moving average of $45.97.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on CRSP shares. HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Bank of America dropped their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Morgan Stanley increased their price target on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Finally, Evercore ISI upgraded shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their price target for the stock from $60.00 to $99.00 in a research report on Friday, February 14th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $74.40.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently made changes to their positions in CRSP. International Assets Investment Management LLC purchased a new stake in CRISPR Therapeutics in the 3rd quarter valued at about $1,825,000. Mirae Asset Global Investments Co. Ltd. boosted its position in CRISPR Therapeutics by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,080 shares of the company’s stock valued at $146,000 after buying an additional 545 shares during the period. Pinnacle Associates Ltd. purchased a new stake in CRISPR Therapeutics in the 3rd quarter valued at about $188,000. HM Payson & Co. boosted its position in CRISPR Therapeutics by 115.7% in the 3rd quarter. HM Payson & Co. now owns 2,330 shares of the company’s stock valued at $109,000 after buying an additional 1,250 shares during the period. Finally, Congress Asset Management Co. boosted its position in CRISPR Therapeutics by 2.8% in the 3rd quarter. Congress Asset Management Co. now owns 65,768 shares of the company’s stock valued at $3,090,000 after buying an additional 1,788 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.